Anti-Cleaved PARP1 antibody [Y34]
- RabMAb
- Recombinant
- KO Validated
- Lab Essentials
- 20ul selling size
- What is this?
5
(1 Review)
|
(86 Publications)
Rabbit Recombinant Monoclonal PARP1 antibody. Suitable for ICC/IF, IP, WB, Flow Cyt (Intra) and reacts with Human samples. Cited in 86 publications.
View Alternative Names
ADPRT, PPOL, PARP1, Poly [ADP-ribose] polymerase 1, PARP-1, ADP-ribosyltransferase diphtheria toxin-like 1, DNA ADP-ribosyltransferase PARP1, NAD(+) ADP-ribosyltransferase 1, Poly[ADP-ribose] synthase 1, Protein poly-ADP-ribosyltransferase PARP1, ARTD1, ADPRT 1
- Flow Cyt (Intra)
Unknown
Flow Cytometry (Intracellular) - Anti-Cleaved PARP1 antibody [Y34] (AB32561)
Primary ab 1/50 dilution (0.5μg / Red). Secondary abGoat anti rabbit IgG (FITC). Secondary ab concentration 1/150 dilution. Cell line Jurkat (human acute T cell leukemia) treated with (Right) or without (Left) 4μM Camptothecin for 5h. Fixative 4% paraformaldehyde. Datasheet comment Intracellular flow cytometric analysis of apoptotic and non-apoptotic Jurkat cells using anti-cleaved PARP1 RabMAb (ab32561). Jurkat cells were either left untreated (A) or treated with camptothecin (4 uM, 5 hr) to induce apoptosis (B). Cells were fixed and permeabilized , and then stained with anti-cleaved PARP1. The results indicate that 43% of cells were positive for cleaved PARP1 (B, M2) after treatment, compared to 9% positive without treatment (A, M2).
- IP
Lab
Immunoprecipitation - Anti-Cleaved PARP1 antibody [Y34] (AB32561)
Purified ab32561 at 1/50 dilution (2μg) immunoprecipitating Cleaved PARP1 in HeLa whole cell lysate.
Lane 1 (input) : HeLa (Human cervix adenocarcinoma epithelial cell) whole cell lysate 10μg
Lane 2 (+) : ab32561 + HeLa whole cell lysate.
Lane 3 (-) : Rabbit monoclonal IgG (ab172730) instead of ab32561 in HeLa whole cell lysate.
VeriBlot for IP Detection Reagent (HRP) (ab131366) (1/1000 dilution) was used for Western blotting.
Blocking Buffer and concentration : 5% NFDM/TBST.
Diluting buffer and concentration : 5% NFDM/TBST.
Observed band size : 85 kDa
All lanes:
Immunoprecipitation - Anti-Cleaved PARP1 antibody [Y34] (ab32561)
Predicted band size: 113 kDa
false
- WB
Lab
Western blot - Anti-Cleaved PARP1 antibody [Y34] (AB32561)
Lane 1 : Wild type HAP1 (untreated) whole cell lysate (20 μg)
Lane 2 : PARP1 (untreated) knockout HAP1 (untreated) whole cell lysate (20 μg)
Lane 3 : HeLa (untreated) whole cell lysate (20 μg)
Lane 4 : HAP1 (staurosporin treated, 1 u M, 4 hr) whole cell lysate (20 μg)
Lane 5 : PARP1 (staurosporin treated, 1 uM, 4 hr) knockout HAP1 whole cell lysate (20 μg)
Lane 6 : HeLa (staurosporin treated, 1 uM, 4 hr) whole cell lysate (20 μg)
Lanes 1 - 6 : Merged signal (red and green). Green - ab32561 observed at 100 kDa. Red - loading control, ab8245, observed at 37 kDa.
ab32561 was shown to specifically react with PARP1 (untreated) when PARP1 (untreated) knockout samples were used. Wild-type and PARP1 (untreated) knockout samples were subjected to SDS-PAGE. ab32561 and ab8245 (Mouse anti GAPDH loading control) were incubated overnight at 4°C at 1000 dilution and 1/10000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed ab216773 and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed ab216776 secondary antibodies at 1/10000 dilution for 1 hour at room temperature before imaging.
All lanes:
Western blot - Anti-Cleaved PARP1 antibody [Y34] (ab32561)
Predicted band size: 113 kDa
false
- WB
Unknown
Western blot - Anti-Cleaved PARP1 antibody [Y34] (AB32561)
All lanes:
Western blot - Anti-Cleaved PARP1 antibody [Y34] (ab32561) at 1/1000 dilution
Lane 1:
Un-treated Jurkat cell lysate.
Lane 2:
Jurkat cell lysate treated with Camptothecin.
Predicted band size: 113 kDa
Observed band size: 85 kDa
false
Related conjugates and formulations (4)
-
519 Alexa Fluor® 488
Alexa Fluor® 488 Anti-Cleaved PARP1 antibody [Y34]
-
HRP Anti-Cleaved PARP1 antibody [Y34]
-
Anti-Cleaved PARP1 antibody [Y34] - BSA and Azide free
-
665 Alexa Fluor® 647
Alexa Fluor® 647 Anti-Cleaved PARP1 antibody [Y34]
Reactivity data
Product details
Species reactivity
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species.
Please contact us for more information.
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
Properties and storage information
Form
Purification technique
Storage buffer
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
The enzymatic function of PARP1 involves the transfer of ADP-ribose units from NAD+ to target proteins a process known as ADP-ribosylation. PARP1 operates as a part of the base excision repair complex essential in DNA repair processes. The cleaved form of PARP1 no longer facilitates DNA repair marking a shift towards apoptosis. When PARP1 is cleaved it indicates caspase activity implying cells are undergoing programmed cell death.
Pathways
Cleaved PARP1 is deeply involved in the apoptosis and DNA damage response pathways. In the apoptosis pathway PARP1 interacts with key proteins like caspase-3 which cleaves PARP during apoptosis. In the DNA damage response PARP1 collaborates with proteins such as XRCC1 facilitating the base excision repair pathway important for fixing single-strand DNA breaks. These pathways highlight the dual role of PARP1 in promoting cell survival through repair and cell death via apoptosis.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (86)
Recent publications for all applications. Explore the full list and refine your search
Scientific reports 15:19695 PubMed40467837
2025
Applications
Unspecified application
Species
Unspecified reactive species
Clinical & experimental metastasis 42:12 PubMed39856383
2025
Applications
Unspecified application
Species
Unspecified reactive species
Journal of translational medicine 22:889 PubMed39358756
2024
Applications
Unspecified application
Species
Unspecified reactive species
International journal of molecular sciences 25: PubMed38892310
2024
Applications
Unspecified application
Species
Unspecified reactive species
Heliyon 10:e23831 PubMed38332874
2024
Applications
Unspecified application
Species
Unspecified reactive species
Heliyon 9:e23079 PubMed38144346
2023
Applications
Unspecified application
Species
Unspecified reactive species
Cell death & disease 14:347 PubMed37268653
2023
Applications
Unspecified application
Species
Unspecified reactive species
Bioscience trends 17:136-147 PubMed36823043
2023
Applications
Unspecified application
Species
Unspecified reactive species
Journal of oncology 2022:8545441 PubMed36317123
2022
Applications
Unspecified application
Species
Unspecified reactive species
Experimental and therapeutic medicine 24:706 PubMed36382092
2022
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com